JOSÉ JAVIER
FERNÁNDEZ RUIZ
Catedrático de universidad
Isabel
Lastres Becker
Isabel Lastres Becker-rekin lankidetzan egindako argitalpenak (24)
2022
-
New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Biomolecules, Vol. 12, Núm. 9
2021
-
Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration
Acta Neuropathologica Communications, Vol. 9, Núm. 1
2010
-
A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice
PLoS ONE, Vol. 5, Núm. 7, pp. 1-15
2009
-
Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease
GLIA, Vol. 57, Núm. 11, pp. 1154-1167
2006
-
An overview of Parkinson's disease and the cannabinoid system and possible benefits of cannabinoid-based treatments
Current Medicinal Chemistry, Vol. 13, Núm. 30, pp. 3705-3718
2005
-
Cannabinoid CB1 receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice
Brain Research, Vol. 1046, Núm. 1-2, pp. 195-206
-
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease
Neurobiology of Disease, Vol. 19, Núm. 1-2, pp. 96-107
2004
-
Involvement of the endocannabinoid system in motor disorders
Current Medicinal Chemistry - Central Nervous System Agents, Vol. 4, Núm. 3, pp. 175-182
-
Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: In vivo and in vitro evidence
Brain Research, Vol. 1007, Núm. 1-2, pp. 152-159
-
Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo
NeuroReport, Vol. 15, Núm. 15, pp. 2375-2379
2003
-
Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease
Journal of Neurochemistry, Vol. 84, Núm. 5, pp. 1097-1109
-
Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate
NeuroReport, Vol. 14, Núm. 6, pp. 813-816
-
The endocannabinoid system and Huntington's disease.
Current drug targets. CNS and neurological disorders, Vol. 2, Núm. 5, pp. 335-347
2002
-
Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease
Synapse, Vol. 44, Núm. 1, pp. 23-35
-
Endocannabinoids and basal ganglia functionality
Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 66, Núm. 2-3, pp. 257-267
-
Loss of cannabinoid CB1 receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease
Neurotoxicity Research, Vol. 4, Núm. 7-8, pp. 601-608
-
Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease
Brain Research, Vol. 929, Núm. 2, pp. 236-242
-
The endogenous cannabinoid system and the basal ganglia: Biochemical, pharmacological, and therapeutic aspects
Pharmacology and Therapeutics, Vol. 95, Núm. 2, pp. 137-152
2001
-
Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration
Journal of Neurochemistry, Vol. 78, Núm. 6, pp. 1415-1427
-
Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease
NeuroReport, Vol. 12, Núm. 10, pp. 2125-2129